Reactive oxygen species-responsive and scavenging polyurethane nanoparticles for treatment of osteoarthritis in vivo

Dexamethasone-loaded ROS-responsive poly(thioketal) nanoparticles suppress inflammation and oxidative stress of acute lung injury

“…The ROS-responsive polymer PPADT had a relatively low molecular weight (4 kDa) and is thus degraded very fast [ 17 ]. Due to the low glass transition temperature (Tg) (Tg = 5 °C), the NPs prepared of PTKU easily undergo aggregation and morphology alteration over time [ 18 ]. In this study, PPADT and PTKU (w/w, 3:1) were blended to prepare the NPs with better stability, morphology ( Fig.…”

“…PPADT was synthesized via condensation polymerization [ 17 ], which had a molecular weight of 4 kDa and polymer dispersity index (PDI) of 2.17 determined by gel permeation chromatography (GPC). PTKU synthesized in our lab [ 18 ] had a molecular weight of 23.8 kDa and PDI of 1.63.…”

Recent Advances in Reactive Oxygen Species (ROS)-Responsive Polyfunctional Nanosystems 3.0 for the Treatment of Osteoarthritis

“…Diisocyanate ROS-responsive group PTK is cleavable, then release DEX. [ 108 ] PEG-PTK-PEG@DA Micelle Osteoclasts 1. PTK (ROS-responsive) 2.…”

“…PTKU@DEXNPs show good cartilage protection and elimination of inflammation in a monosodium iodoacetate (MIA)-induced OA model. 108 …”

ROS-responsive polymer nanoparticles with enhanced loading of dexamethasone effectively modulate the lung injury microenvironment

“…The release of pro-inflammatory cytokines elicits an immune response and recruits neutrophils to the inflamed tissue, which further release noxious mediators such as reactive oxygen species (ROS) and myeloperoxidase (MPO) [5] . ROS are presumed to serve as a host defense against pathogens, and their concentration is thought to be controlled by the balance between production and scavenging [6] . The excessive formation of ROS or insufficient clearance of ROS will result in a variety of pathological diseases such as asthma, chronic obstructive pulmonary disease (COPD), and ARDS 7 , 8 , 9 .…”